Rice Michael's Form 4 filing
Biolife Solutions Inc (BLFS) · filed Apr 13, 2022
- Accession no.
- 0001437749-22-008915
- Filed
- Apr 13, 2022
- Trade date
- Apr 11-13, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $386.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rice MichaelCIK 0001389512 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $1.90 | +$19,000 | 337,155 | Direct | |
| Apr 11, 2022 | Common Stock | SSaleDisposed | −10,000 | $19.55F2 | −$195,500 | 327,155 | Direct | |
| Apr 12, 2022 | Common Stock | MOption exerciseAcquired | +57,736 | –F3 | – | 384,891 | Direct | |
| Apr 13, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $1.90 | +$19,000 | 394,891 | Direct | |
| Apr 13, 2022 | Common Stock | SSaleDisposed | −10,000 | $19.06F4 | −$190,600 | 384,891 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 11, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 70,000 | Direct | |
| Apr 12, 2022 | Common Stock | MOption exerciseDisposed | −57,736 | $0.00 | $0 | 0 | Direct | |
| Apr 13, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 60,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.